Safe Prescribing — MCQs
On this page
A 55-year-old man is prescribed clozapine for treatment-resistant schizophrenia. He is currently on day 18 of titration, taking 200mg daily in divided doses. His full blood count today shows: Hb 142 g/L, WBC 2.8 × 10⁹/L, neutrophils 1.2 × 10⁹/L, platelets 245 × 10⁹/L. He is clinically well with no signs of infection. What is the most appropriate immediate action?
A 69-year-old man with non-valvular atrial fibrillation has a CHA₂DS₂-VASc score of 4 and HAS-BLED score of 3. He experienced a fall resulting in a subdural haematoma requiring surgical evacuation three weeks ago. He has made a good neurological recovery. His past medical history includes hypertension, type 2 diabetes, previous ischaemic stroke (18 months ago), and chronic kidney disease stage 3a (eGFR 52 ml/min/1.73m²). What is the most appropriate management of his stroke prevention?
A 41-year-old woman with type 1 diabetes is admitted to hospital for elective laparoscopic cholecystectomy. Her usual insulin regimen is insulin glargine 24 units at bedtime and insulin aspart 8 units before each meal. She is scheduled for surgery at 2 PM and is third on the afternoon theatre list. What is the most appropriate insulin management on the day of surgery?
A 64-year-old woman with atrial fibrillation on dabigatran 150mg twice daily is admitted with an acute upper gastrointestinal bleed. Her haemoglobin has dropped from 125 g/L to 78 g/L. Endoscopy shows a bleeding duodenal ulcer. She is haemodynamically stable after fluid resuscitation. Her renal function shows eGFR 68 ml/min/1.73m². What is the most appropriate immediate management of her anticoagulation?
What is the recommended maximum duration for which a patient should remain on a treatment dose of low molecular weight heparin (LMWH) before reviewing the need for anti-Xa level monitoring in the context of renal impairment?
A 72-year-old man with type 2 diabetes is admitted with sepsis secondary to a urinary tract infection. His regular medications include metformin 1g twice daily, gliclazide 80mg twice daily, and ramipril 10mg once daily. His admission blood results show: sodium 138 mmol/L, potassium 4.2 mmol/L, creatinine 185 μmol/L (baseline 95 μmol/L), glucose 18.2 mmol/L. Which medication should be stopped immediately?
A 58-year-old woman is started on treatment for tuberculosis. Her regimen includes rifampicin, isoniazid, pyrazinamide, and ethambutol. She has been taking warfarin for five years following a pulmonary embolism. What is the most appropriate management of her anticoagulation?
Understanding the principles of insulin prescribing for surgical patients, which statement regarding the management of long-acting insulin analogues during the perioperative period is correct?
A 57-year-old woman is taking warfarin following a mechanical mitral valve replacement. Her target INR is 2.5-3.5. She has been stable on warfarin 4mg daily for 6 months with INR consistently 2.8-3.2. She now requires treatment for newly diagnosed hypothyroidism and is started on levothyroxine. How should her warfarin therapy be managed?
A 66-year-old man with type 2 diabetes is reviewed in clinic. His diabetes is managed with insulin detemir 34 units in the morning and 28 units at bedtime, plus metformin 1g twice daily. His HbA1c is 76 mmol/mol (9.1%) and he reports frequent missed insulin doses because he 'forgets which dose to take when'. His BMI is 34 kg/m². He has no complications. What is the most appropriate modification to improve adherence and glycaemic control?
Safe Prescribing UK Medical PG Practice Questions and MCQs
Question 191: A 55-year-old man is prescribed clozapine for treatment-resistant schizophrenia. He is currently on day 18 of titration, taking 200mg daily in divided doses. His full blood count today shows: Hb 142 g/L, WBC 2.8 × 10⁹/L, neutrophils 1.2 × 10⁹/L, platelets 245 × 10⁹/L. He is clinically well with no signs of infection. What is the most appropriate immediate action?
- A. Continue clozapine at current dose and repeat FBC in one week
- B. Stop clozapine immediately, admit for urgent haematology assessment, and never rechallenge
- C. Reduce clozapine dose by 50%, repeat FBC in 48 hours, and increase dose cautiously if neutrophils rise
- D. Stop clozapine immediately, repeat FBC in 24 hours, and do not rechallenge if neutropenia confirmed (Correct Answer)
- E. Continue clozapine but increase monitoring frequency to twice weekly FBC until neutrophils normalise
Explanation: ***Stop clozapine immediately, repeat FBC in 24 hours, and do not rechallenge if neutropenia confirmed***- This patient's **absolute neutrophil count (ANC)** is 1.2 × 10⁹/L, which falls into the **Red Light** category (<1.5 × 10⁹/L) of the clozapine monitoring protocol.- The drug must be **ceased immediately** due to the risk of progressing to **agranulocytosis**; a repeat FBC within 24 hours is required to track recovery and confirm the finding.*Continue clozapine at current dose and repeat FBC in one week*- Continuing the drug with a **Red Light** result is unsafe and violates clozapine safety protocols designed to prevent **fatal sepsis**.- Weekly monitoring is part of the standard schedule for the first 18 weeks but is insufficient when **severe neutropenia** is detected.*Stop clozapine immediately, admit for urgent haematology assessment, and never rechallenge*- While the drug must stop, **urgent admission** is typically reserved for patients who are clinically unwell or have **agranulocytosis** (ANC <0.5 × 10⁹/L).- Rechallenge is generally prohibited after a **Red Light** event, but the immediate clinical priority in an asymptomatic patient is cessation and outpatient monitoring.*Reduce clozapine dose by 50%, repeat FBC in 48 hours, and increase dose cautiously if neutrophils rise*- Dose reduction is not an acceptable response to **Red Light neutropenia** because the reaction is often **idiosyncratic** rather than dose-dependent.- The protocol mandates **complete cessation** rather than dose manipulation to ensure patient safety and bone marrow recovery.*Continue clozapine but increase monitoring frequency to twice weekly FBC until neutrophils normalise*- This management strategy is appropriate for the **Amber Light** category (ANC 1.5–2.0 × 10⁹/L), where monitoring is increased but the drug is continued.- Since the patient’s ANC is **1.2 × 10⁹/L**, this lenient approach would expose the patient to a dangerous risk of further **marrow suppression**.
Question 192: A 69-year-old man with non-valvular atrial fibrillation has a CHA₂DS₂-VASc score of 4 and HAS-BLED score of 3. He experienced a fall resulting in a subdural haematoma requiring surgical evacuation three weeks ago. He has made a good neurological recovery. His past medical history includes hypertension, type 2 diabetes, previous ischaemic stroke (18 months ago), and chronic kidney disease stage 3a (eGFR 52 ml/min/1.73m²). What is the most appropriate management of his stroke prevention?
- A. Prescribe aspirin 75mg once daily as anticoagulation is contraindicated following intracranial haemorrhage
- B. Arrange left atrial appendage occlusion device and avoid all anticoagulation
- C. Restart anticoagulation with apixaban at 4-6 weeks post-haemorrhage after MDT discussion and imaging confirmation of haematoma resolution (Correct Answer)
- D. Defer anticoagulation indefinitely as HAS-BLED score of 3 indicates high bleeding risk
- E. Start warfarin with target INR 2.0-2.5 (lower than standard) to balance stroke and bleeding risk
Explanation: ***Restart anticoagulation with apixaban at 4-6 weeks post-haemorrhage after MDT discussion and imaging confirmation of haematoma resolution*** - In patients with a high **CHA₂DS₂-VASc** score (4), the risk of ischemic stroke often outweighs the risk of recurrent **intracranial hemorrhage**, especially when the bleed was a traumatic **subdural haematoma** rather than spontaneous. - Current guidelines suggest restarting **DOACs** rather than warfarin between 4–8 weeks post-event, provided **MDT discussion** and repeat imaging confirm the resolution of the hematoma. *Prescribe aspirin 75mg once daily as anticoagulation is contraindicated following intracranial haemorrhage* - **Aspirin** provides significantly inferior stroke prevention compared to anticoagulants in patients with **atrial fibrillation**. - Antiplatelet therapy still carries a notable risk of bleeding and is not considered a safe or effective long-term alternative to anticoagulation in this high-risk patient. *Arrange left atrial appendage occlusion device and avoid all anticoagulation* - **Left atrial appendage occlusion (LAAO)** is typically reserved for patients with absolute, permanent contraindications to anticoagulation where the bleeding risk is prohibitive. - Recent evidence and the traumatic nature of this bleed suggest that **anticoagulation** can often be safely resumed, making LAAO a second-line consideration here. *Defer anticoagulation indefinitely as HAS-BLED score of 3 indicates high bleeding risk* - A **HAS-BLED** score of 3 or more indicates a higher risk of bleeding but is not an absolute contraindication; it serves as a tool to identify and mitigate **modifiable risk factors**. - Indefinite deferral leaves the patient at a high (>4% per year) risk of a potentially fatal or disabling **ischemic stroke**. *Start warfarin with target INR 2.0-2.5 (lower than standard) to balance stroke and bleeding risk* - **DOACs** like apixaban are generally preferred over **warfarin** in this scenario because they are associated with a significantly lower risk of secondary intracranial hemorrhage. - There is no clinical evidence to support a lower **target INR** for stroke prevention in AF, as it results in sub-therapeutic protection without guaranteed safety.
Question 193: A 41-year-old woman with type 1 diabetes is admitted to hospital for elective laparoscopic cholecystectomy. Her usual insulin regimen is insulin glargine 24 units at bedtime and insulin aspart 8 units before each meal. She is scheduled for surgery at 2 PM and is third on the afternoon theatre list. What is the most appropriate insulin management on the day of surgery?
- A. Omit morning glargine and all aspart doses; start variable rate intravenous insulin infusion (VRIII) from 7 AM
- B. Give 80% of usual glargine dose in the morning; omit all aspart doses; start VRIII at 11 AM
- C. Give usual glargine dose the night before; omit breakfast and lunch aspart; start VRIII from 7 AM with glucose/saline infusion (Correct Answer)
- D. Give usual glargine dose the night before; give breakfast aspart with light breakfast; start VRIII from 11 AM when fasting begins
- E. Convert to VRIII at midnight the night before surgery and continue until eating and drinking postoperatively
Explanation: ***Give usual glargine dose the night before; omit breakfast and lunch aspart; start VRIII from 7 AM with glucose/saline infusion*** - Patients with **Type 1 Diabetes** require continuous **basal insulin** (like glargine) to prevent ketosis; this should be continued at the usual dose the night before surgery. - Since the patient is scheduled for an afternoon surgery and will be **nil by mouth (NBM)** after breakfast, a **Variable Rate Intravenous Insulin Infusion (VRIII)** must be started by 7–8 AM to manage glycemic control during the fasting period with a concomitant **glucose/saline infusion** to prevent hypoglycemia. *Omit morning glargine and all aspart doses; start variable rate intravenous insulin infusion (VRIII) from 7 AM* - Basal insulin (like glargine) should **never be completely omitted** in Type 1 Diabetes patients, as it provides the essential background insulin needed to prevent **diabetic ketoacidosis (DKA)**. - While starting VRIII at 7 AM is appropriate, omitting the long-acting insulin entirely risks significant **hyperglycemia** and DKA, especially if the VRIII is interrupted or not started promptly. *Give 80% of usual glargine dose in the morning; omit all aspart doses; start VRIII at 11 AM* - Glargine is a **long-acting insulin analogue** usually given at bedtime or once daily; arbitrarily reducing the dose or giving it in the morning on the day of surgery can disrupt basal glycemic control. - Starting **VRIII at 11 AM is too late** for a patient who is third on an afternoon list, as they would have been fasting for several hours without adequate glucose or insulin cover, increasing the risk of **hypoglycemia** or **hyperglycemia**. *Give usual glargine dose the night before; give breakfast aspart with light breakfast; start VRIII from 11 AM when fasting begins* - Administering short-acting **insulin aspart** with a light breakfast is risky for surgical patients as it may lead to **hypoglycemia** if the surgical schedule changes, is delayed, or if the patient cannot tolerate the food. - For a patient who is third on an afternoon list, they should generally be **nil by mouth (NBM)** from earlier in the morning, with **VRIII and dextrose** started to maintain glycemic stability. *Convert to VRIII at midnight the night before surgery and continue until eating and drinking postoperatively* - Starting **VRIII at midnight** the night before elective day-time surgery is generally **unnecessary** and overly aggressive, increasing the patient's discomfort, the monitoring burden, and the risk of **hypoglycemia** during the night. - The standard approach for Type 1 DM patients undergoing elective surgery is to maintain their **subcutaneous basal insulin** (often at usual or reduced dose) and only initiate the intravenous infusion (VRIII with dextrose) on the morning of the procedure when fasting begins.
Question 194: A 64-year-old woman with atrial fibrillation on dabigatran 150mg twice daily is admitted with an acute upper gastrointestinal bleed. Her haemoglobin has dropped from 125 g/L to 78 g/L. Endoscopy shows a bleeding duodenal ulcer. She is haemodynamically stable after fluid resuscitation. Her renal function shows eGFR 68 ml/min/1.73m². What is the most appropriate immediate management of her anticoagulation?
- A. Omit next dose of dabigatran and restart at reduced dose of 110mg twice daily after 48 hours
- B. Administer idarucizumab immediately and restart dabigatran at 110mg twice daily after haemostasis
- C. Administer idarucizumab, achieve haemostasis, and restart anticoagulation with warfarin after 7-14 days
- D. Withhold dabigatran, monitor closely, and consider restarting at same dose once haemostasis achieved and patient stable (Correct Answer)
- E. Administer prothrombin complex concentrate and vitamin K to reverse the effect
Explanation: ***Withhold dabigatran, monitor closely, and consider restarting at same dose once haemostasis achieved and patient stable***- In a **haemodynamically stable** patient with non-life-threatening bleeding, the primary management for **DOACs** is to withhold the medication and rely on its relatively short **half-life** for clearance.- Since the patient has **normal-to-mildly impaired renal function** (eGFR 68), dabigatran will be cleared within roughly 24-48 hours without the need for aggressive reversal agents.*Omit next dose of dabigatran and restart at reduced dose of 110mg twice daily after 48 hours*- Dose reduction from 150mg to 110mg is typically indicated by **age over 80**, concomitant **verapamil** use, or high bleeding risk, rather than a single treatable GI event.- Restarting anticoagulation too early (within 48 hours) after a significant **haemoglobin drop** and a visible bleeding ulcer increases the risk of **re-bleeding**.*Administer idarucizumab immediately and restart dabigatran at 110mg twice daily after haemostasis*- **Idarucizumab** is a specific reversal agent reserved for **life-threatening bleeding**, uncontrolled haemorrhage, or patients requiring **emergency surgery**.- This patient is **haemodynamically stable** after fluids, making the use of an expensive, specific reversal agent inappropriate in this clinical context.*Administer idarucizumab, achieve haemostasis, and restart anticoagulation with warfarin after 7-14 days*- Switching to **warfarin** is not indicated here, as **DOACs** are generally preferred for stroke prevention in **atrial fibrillation** due to a better safety profile regarding intracranial haemorrhage.- As noted previously, **idarucizumab** is not indicated in stable patients where supportive care and withholding the drug are sufficient.*Administer prothrombin complex concentrate and vitamin K to reverse the effect*- **Vitamin K** and **Prothrombin Complex Concentrate (PCC)** are used to reverse **warfarin**, but they do not specifically reverse the direct thrombin inhibition of **dabigatran**.- While PCC may be considered in severe DOAC bleeding if a specific agent is unavailable, it is not the first-line treatment for **dabigatran** reversal nor necessary in a stable patient.
Question 195: What is the recommended maximum duration for which a patient should remain on a treatment dose of low molecular weight heparin (LMWH) before reviewing the need for anti-Xa level monitoring in the context of renal impairment?
- A. 24 hours
- B. 48 hours
- C. 72 hours (Correct Answer)
- D. 5-7 days
- E. Anti-Xa monitoring is not required in renal impairment
Explanation: ***72 hours*** - In patients with **renal impairment**, LMWH is not cleared efficiently, necessitating a review and **anti-Xa monitoring** typically after 3-4 doses or approximately **72 hours**. - This timeframe allows the drug to reach a **steady state**, ensuring the peak level measured reflects the actual clinical accumulation risk. *24 hours* - Monitoring at **24 hours** is generally too early as the drug has likely not reached a **steady state concentration** in the blood. - Clinical guidelines prioritize safety by allowing enough time for **bioaccumulation** to become detectable via laboratory testing. *48 hours* - While some accumulation occurs, **48 hours** is usually insufficient to represent the maximum level reached before a dosage adjustment is considered. - Standard protocols specifically identify the **third or fourth dose** (reaching the 72-hour mark) as the optimal window for **anti-Xa level** sampling. *5-7 days* - Waiting **5-7 days** poses a significant danger of **over-anticoagulation** and life-threatening bleeding in patients with a low **Creatinine Clearance**. - Routine monitoring for high-risk medications must occur sooner than a week to mitigate the risk of **dose-dependent toxicity**. *Anti-Xa monitoring is not required in renal impairment* - This statement is incorrect because LMWH is **renally excreted** and failure to monitor leads to a high risk of **hemorrhagic complications**. - In cases of severe renal failure (eGFR <30), **unfractionated heparin** is often preferred, but if LMWH is used, **anti-Xa monitoring** is mandatory.
Question 196: A 72-year-old man with type 2 diabetes is admitted with sepsis secondary to a urinary tract infection. His regular medications include metformin 1g twice daily, gliclazide 80mg twice daily, and ramipril 10mg once daily. His admission blood results show: sodium 138 mmol/L, potassium 4.2 mmol/L, creatinine 185 μmol/L (baseline 95 μmol/L), glucose 18.2 mmol/L. Which medication should be stopped immediately?
- A. Both metformin and ramipril (Correct Answer)
- B. Gliclazide only
- C. Metformin only
- D. Ramipril only
- E. All three medications should be stopped
Explanation: ***Both metformin and ramipril*** - **Metformin** must be stopped during **sepsis** and **acute kidney injury (AKI)** because it is renally excreted, and its accumulation carries a high risk of life-threatening **lactic acidosis**. - **Ramipril** (an ACE inhibitor) should be withheld as it can worsen renal perfusion and increase the risk of **hyperkalemia** in patients with a rising **creatinine** (indicating AKI). *Gliclazide only* - While **sulfonylureas** like gliclazide require close monitoring for hypoglycemia during illness, they are not the primary concern regarding **nephrotoxicity** or metabolic acidosis in this patient. - Stopping only this medication would fail to address the serious risks posed by the current use of **metformin** and **ramipril** in the context of AKI and sepsis. *Metformin only* - Stopping **metformin** is essential due to the side effect of **lactic acidosis**, but it is insufficient management on its own for this patient's acute kidney injury. - **Ramipril** must also be discontinued because it interferes with autoregulation of the **glomerular filtration rate (GFR)** during acute illness and dehydration, potentially worsening AKI. *Ramipril only* - While **ramipril** must be stopped to avoid further deterioration of **renal function**, this choice ignores the severe risk of **lactic acidosis** from continuing metformin. - Guidelines for **"sick day rules"** strictly dictate that both ACE inhibitors and metformin should be paused in the context of significant **sepsis** and AKI. *All three medications should be stopped* - **Gliclazide** is often continued under close supervision to manage hyperglycemia in acute illness, though doses may be adjusted; it does not carry the same systemic danger as the other two in AKI. - Total cessation of all diabetes medications may lead to **severe hyperglycemia**, whereas the priority is removing **nephrotoxic** and acidotic-triggering agents.
Question 197: A 58-year-old woman is started on treatment for tuberculosis. Her regimen includes rifampicin, isoniazid, pyrazinamide, and ethambutol. She has been taking warfarin for five years following a pulmonary embolism. What is the most appropriate management of her anticoagulation?
- A. Switch to low molecular weight heparin for the duration of tuberculosis treatment
- B. Continue warfarin and monitor INR weekly for the first month, then monthly
- C. Switch to a direct oral anticoagulant (DOAC) such as apixaban
- D. Continue warfarin and monitor INR 3-4 times in the first week, then frequently until stable (Correct Answer)
- E. Discontinue anticoagulation as the tuberculosis treatment takes priority
Explanation: ***Continue warfarin and monitor INR 3-4 times in the first week, then frequently until stable*** - **Rifampicin** is a potent **cytochrome P450 enzyme inducer**, which significantly increases the metabolism of **warfarin**, leading to a drop in **INR** and increased thrombotic risk. - Frequent monitoring is essential because the dose of **warfarin** may need to be increased by **50-100%** to maintain a therapeutic range during co-administration. *Switch to low molecular weight heparin for the duration of tuberculosis treatment* - While **LMWH** avoids the P450 interaction, prescribing it for the full 6-month course of **TB treatment** is unnecessary and burdensome for the patient. - **Warfarin** can be maintained safely provided that **INR monitoring** and dose adjustments are performed diligently. *Continue warfarin and monitor INR weekly for the first month, then monthly* - Monitoring **weekly** is insufficient because the inducing effect of **rifampicin** begins within days and can cause a rapid decline in **anticoagulation levels**. - Sub-therapeutic **INR** levels in a patient with a history of **pulmonary embolism** pose an immediate risk of recurrent thrombosis. *Switch to a direct oral anticoagulant (DOAC) such as apixaban* - **Rifampicin** also induces **P-glycoprotein (P-gp)** and **CYP3A4**, which are the same pathways used to metabolize **DOACs** like **apixaban**. - Using **DOACs** with rifampicin is generally contraindicated as it leads to significantly reduced plasma concentrations and potential **treatment failure**. *Discontinue anticoagulation as the tuberculosis treatment takes priority* - **Tuberculosis treatment** does not necessitate the cessation of **anticoagulation**, especially in a patient with a high-risk history of **pulmonary embolism**. - Both conditions must be managed simultaneously; stopping **warfarin** would expose the patient to life-threatening **thromboembolic events**.
Question 198: Understanding the principles of insulin prescribing for surgical patients, which statement regarding the management of long-acting insulin analogues during the perioperative period is correct?
- A. Long-acting insulin analogues should always be stopped when a variable rate intravenous insulin infusion is commenced
- B. Long-acting insulin analogues should be continued at the usual dose throughout the perioperative period in patients with type 1 diabetes (Correct Answer)
- C. Long-acting insulin analogues should be reduced by 50% on the day of surgery in all patients
- D. Long-acting insulin analogues should be replaced with short-acting insulin when patients are fasted
- E. Long-acting insulin analogues can be omitted for up to 24 hours without significant metabolic consequences
Explanation: ***Long-acting insulin analogues should be continued at the usual dose throughout the perioperative period in patients with type 1 diabetes***- Patients with **Type 1 Diabetes** have an absolute insulin deficiency and require continuous **basal insulin** to prevent the development of **diabetic ketoacidosis (DKA)**.- Continuing the long-acting analogue provide a **safety net** if the intravenous infusion is interrupted, ensuring the patient is never without circulating insulin.*Long-acting insulin analogues should always be stopped when a variable rate intravenous insulin infusion is commenced*- Stopping basal insulin during a **Variable Rate Intravenous Insulin Infusion (VRIII)** is dangerous as it significantly increases the risk of **rebound hyperglycemia** and DKA when the drip is discontinued.- Current **JBDS guidelines** recommend maintaining background insulin to facilitate a smoother transition back to subcutaneous regimens after surgery.*Long-acting insulin analogues should be reduced by 50% on the day of surgery in all patients*- Routine reduction by 50% for **Type 1 diabetics** is not typically recommended as it may lead to inadequate **basal coverage** during the stress of surgery.- While doses might be slightly adjusted (e.g., a 20% reduction) in some **Type 2 diabetics** or specific high-risk scenarios, it is not a universal rule for "all patients."*Long-acting insulin analogues should be replaced with short-acting insulin when patients are fasted*- Short-acting insulin has a brief duration of action and cannot provide the steady **basal metabolic rate** coverage required over 24 hours.- Relying solely on short-acting insulin during fasting increases the risk of **glycemic instability** and requires more frequent monitoring than a stable long-acting dose.*Long-acting insulin analogues can be omitted for up to 24 hours without significant metabolic consequences*- Omitting insulin in a Type 1 diabetic for 24 hours is life-threatening and can lead to severe **metabolic acidosis** and ketoacidosis within hours.- The **half-life** of intravenous insulin is only minutes; without long-acting subcutaneous insulin, the patient has no protection if the IV line fails.
Question 199: A 57-year-old woman is taking warfarin following a mechanical mitral valve replacement. Her target INR is 2.5-3.5. She has been stable on warfarin 4mg daily for 6 months with INR consistently 2.8-3.2. She now requires treatment for newly diagnosed hypothyroidism and is started on levothyroxine. How should her warfarin therapy be managed?
- A. No change to warfarin dose; levothyroxine does not interact with warfarin
- B. Reduce warfarin dose by 10-20% immediately and check INR in 3-5 days
- C. Increase warfarin dose by 10-20% immediately and check INR in 3-5 days
- D. Continue current warfarin dose and check INR more frequently (weekly) for the first 4-6 weeks of levothyroxine treatment (Correct Answer)
- E. Switch from warfarin to a direct oral anticoagulant to avoid the interaction
Explanation: ***Continue current warfarin dose and check INR more frequently (weekly) for the first 4-6 weeks of levothyroxine treatment***- **Thyroid hormones** increase the catabolism of vitamin K-dependent **clotting factors**, meaning that as the patient reaches a euthyroid state, the anticoagulant effect of warfarin may be **potentiated**, increasing the INR.- Because this metabolic shift occurs gradually as **levothyroxine** levels stabilize, the safest management is **frequent monitoring** rather than an immediate empirical dose adjustment.*No change to warfarin dose; levothyroxine does not interact with warfarin*- This is incorrect because thyroid status directly influences the **metabolic clearance** of clotting factors and changes the body's sensitivity to warfarin.- Failing to monitor the **INR** during thyroid replacement therapy puts the patient at an increased risk of **hemorrhagic complications**.*Reduce warfarin dose by 10-20% immediately and check INR in 3-5 days*- An immediate dose reduction is **premature** as the metabolic effects of levothyroxine take time to manifest and the exact dose requirement change is unpredictable.- Pre-emptive adjustments may lead to a **subtherapeutic INR**, which is dangerous for a patient with a **mechanical mitral valve** requiring a high target range.*Increase warfarin dose by 10-20% immediately and check INR in 3-5 days*- This action is contraindicated because corrected hypothyroidism typically **increases** the effect of warfarin (higher INR), not decreases it.- Increasing the dose would significantly raise the risk of **major bleeding** as the patient transition from a hypothyroid to a euthyroid state.*Switch from warfarin to a direct oral anticoagulant to avoid the interaction*- **Direct oral anticoagulants (DOACs)** are strictly **contraindicated** in patients with **mechanical heart valves** due to a higher risk of thromboembolic events and bleeding compared to warfarin.- Warfarin remains the **gold standard** and only indicated long-term anticoagulant for patients with mechanical mitral valve replacements.
Question 200: A 66-year-old man with type 2 diabetes is reviewed in clinic. His diabetes is managed with insulin detemir 34 units in the morning and 28 units at bedtime, plus metformin 1g twice daily. His HbA1c is 76 mmol/mol (9.1%) and he reports frequent missed insulin doses because he 'forgets which dose to take when'. His BMI is 34 kg/m². He has no complications. What is the most appropriate modification to improve adherence and glycaemic control?
- A. Switch to once-daily insulin glargine U300 and continue metformin
- B. Add a GLP-1 receptor agonist and reduce insulin doses
- C. Switch to premixed insulin (biphasic insulin aspart) twice daily and continue metformin (Correct Answer)
- D. Arrange for district nurses to supervise insulin administration
- E. Continue current regimen but provide a dosette box system for insulin pens
Explanation: ***Switch to premixed insulin (biphasic insulin aspart) twice daily and continue metformin*** - Switching to **premixed (biphasic) insulin** simplifies the regimen by using the same dose or product twice daily with meals, directly addressing the patient's confusion and **missed doses**. - This approach combines **basal and prandial insulin** into a single injection, which is highly effective for patients with type 2 diabetes who struggle with the complexity of multiple insulin titration schedules. *Switch to once-daily insulin glargine U300 and continue metformin* - While **once-daily glargine** simplifies the basal component, it may not provide sufficient **glycaemic control** for a patient with an HbA1c of 9.1% without additional mealtime coverage. - This modification does not solve the need for prandial support, which might eventually lead to an even more complex **basal-bolus** regimen that the patient already struggles with. *Add a GLP-1 receptor agonist and reduce insulin doses* - Adding a **GLP-1 receptor agonist** is beneficial for weight loss and glycaemic control, but it introduces a **new medication class** and potential side effects rather than simplifying the current confusion. - The primary issue is **adherence** due to regimen complexity; adding more varied treatments may further complicate the patient's routine. *Arrange for district nurses to supervise insulin administration* - **District nurse supervision** is a resource-intensive intervention usually reserved for patients with physical or cognitive disabilities who cannot self-administer. - It does not promote **patient autonomy** or address the underlying issue of an unnecessarily complex insulin schedule for a capable patient. *Continue current regimen but provide a dosette box system for insulin pens* - **Dosette boxes** (multi-compartment compliance aids) are designed for oral tablets and cannot be used to organize or store **insulin pens** or injections. - Continuing the current regimen ignores the patient's explicit feedback that the **different dosing schedule** is the cause of his non-adherence.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free